Composite hydrogel for repairing bone-tendon interface as well as preparation method and application of composite hydrogel

By using Sm-sEV/αLA-Gel composite hydrogel material, the problems of insufficient immune regulation and adhesion of existing bone-tendon interface repair materials under inflammatory and osteoporotic conditions are solved, achieving anti-aging and improved mechanical properties, and promoting the overall repair of the bone-tendon interface.

CN121731552APending Publication Date: 2026-03-27SHANGHAI SIXTH PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511957250.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-23
Publication Date
2026-03-27

AI Technical Summary

Technical Problem

Existing bone-tendon interface repair materials lack immunomodulatory capabilities under pathological conditions such as inflammation or osteoporosis, and cannot effectively inhibit the persistent inflammatory response driven by M1 macrophages, leading to the accumulation of pro-inflammatory factors, activation of the cGAS-STING-NF-κB signaling pathway, weakening the osteogenic differentiation potential of BMSCs, and insufficient material adhesion, making it difficult to achieve overall tissue repair under complex pathological conditions.

Method used

Small extracellular vesicles pretreated with quercetin were combined with α-lipoic acid modified gelatin methacryloyl hydrogel (Sm-sEV/αLA-Gel) to construct a porous composite hydrogel, which achieves immune regulation, anti-cellular aging and tissue adhesion, and loads and continuously releases active ingredients through capillary action.

Benefits of technology

It significantly reduces the expression of local tissue aging markers, enhances the mechanical integration strength of the bone-tendon interface, improves the mechanical properties of interface healing, provides a stable repair environment, and promotes the functional recovery of the bone-tendon interface.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121731552A_ABST
    Figure CN121731552A_ABST
Patent Text Reader

Abstract

The invention discloses a composite hydrogel for repairing a bone-tendon interface as well as a preparation method and application of the composite hydrogel. The composite hydrogel comprises human mesenchymal stem cell-derived extracellular vesicles pretreated by quercetin, and a gelatin methylacrylate hydrogel carrier which is modified by alpha-lipoic acid and has a porous structure. The preparation method comprises the following steps: preparing a quercetin-pretreated small extracellular vesicle suspension; preparing a gelatin methylacryloyl compound porous hydrogel modified by alpha-lipoic acid; and the small extracellular vesicles are loaded in the porous structure of the hydrogel. The composite material can effectively inhibit local tissue cell senescence, significantly improve the mechanical strength of a bone-tendon interface after healing, realizes sustained release of bioactive components by using a porous structure, and has a good application prospect in repair of refractory tendon-bone interface injuries such as osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of biological medicine, and particularly relates to a composite hydrogel for repairing bone-tendon interface and a preparation method and application thereof. BACKGROUND

[0002] At present, the materials for repairing bone-tendon interface (BTI) are mainly based on natural or synthetic polymers, which realize local tissue support and regeneration by constructing hydrogels or degradable scaffolds. Among them, the hydrogel materials usually take sodium alginate, gelatin, collagen and polyethylene glycol (PEG) as the matrix, and form a three-dimensional network structure through physical crosslinking or chemical crosslinking, which is used to fill the defect area or provide a cell adhesion microenvironment. The scaffold materials are mostly constructed by using degradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) to construct porous or composite structures, which provide tissue support through suture or mechanical fixation. In order to enhance the biological activity, the existing materials often combine growth factors, drugs or other active ingredients in order to promote the healing of bone-tendon. However, the existing hydrogels are mostly single-phase structures, and the adhesion between the hydrogels and the tissues is weak, so it is difficult to maintain stable positioning in the humid and high dynamic load rotator cuff area. The degree of close integration of the scaffold material with the surrounding tissue is limited. At the same time, the slow-release system (such as BMP-2 and TGF-β3) loaded with growth factors has the problems of high cost, poor stability and easy inactivation in the inflammatory microenvironment, which limits its repair effect under complex pathological conditions.

[0003] The above technical solution has limited repair effect under chronic inflammation or osteoporosis and other pathological conditions. The main reason is that the existing materials generally lack active immune regulation ability, and cannot effectively inhibit the sustained inflammatory response driven by M1 macrophages, resulting in the accumulation of pro-inflammatory factors and the destruction of the BTI microenvironment. At the same time, inflammation can induce bone marrow-derived mesenchymal stem cells (BMSCs) to exhibit a senescent phenotype, activate the cGAS-STING-NF-κB signaling pathway, and thus significantly weaken their osteogenic differentiation potential. The existing repair materials usually only focus on tissue structure repair, and lack means to deal with the key pathological chain of “inflammation-stem cell aging”, making it difficult to achieve good results under the conditions of aging, osteoporosis or high inflammation level.

[0004] Furthermore, BTI repair essentially requires the coordinated regeneration of three tissue types simultaneously: bone, fibrocartilage, and tendon. However, most existing materials can only promote the regeneration of one of these tissue types, lacking the ability to regulate the overall BTI hierarchical structure. In addition, the insufficient adhesion of most hydrogels, limited drug loading capacity of active factors, and the complex preparation processes and stringent cross-linking conditions of some materials make it difficult to simultaneously meet the multiple needs of tissue adhesion, immune regulation, anti-cellular aging, and promotion of bone-fibrocartilage-tendon integration in practical applications.

[0005] In summary, current technologies still lack a functionalized hydrogel material capable of exerting immunomodulatory effects, inhibiting BMSC aging, enhancing local tissue regeneration, and simultaneously promoting the overall repair of BTI structures in adverse microenvironments such as inflammation or osteoporosis. Therefore, developing a novel hydrogel that combines immunomodulatory, anti-aging, tissue adhesion, and bone-tendon interface reconstruction capabilities is of great significance. Summary of the Invention

[0006] The purpose of this invention is to address the shortcomings of existing technologies by providing a composite hydrogel for bone-tendon interface repair, its preparation method, and its application.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows: The first aspect is to provide a composite hydrogel for bone-tendon interface repair, the composite hydrogel comprising quercetin-pretreated small extracellular vesicles and a gelatin methacryloyl hydrogel carrier modified with α-lipoic acid and having a porous structure for loading the small extracellular vesicles.

[0008] Furthermore, the small extracellular vesicles are derived from human mesenchymal stem cells treated with quercetin.

[0009] Furthermore, the human mesenchymal stem cells are selected from adipose-derived stem cells, bone marrow-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or induced pluripotent stem cell-derived mesenchymal stem cells.

[0010] Furthermore, the human mesenchymal stem cells are adipose-derived stem cells.

[0011] The second aspect is to provide a method for preparing the above-mentioned composite hydrogel, including the following steps: (a) Preparation of a suspension of small extracellular vesicles pretreated with quercetin; (b) Prepare a porous hydrogel of gelatin methacryloyl derivative modified with α-lipoic acid, denoted as αLA-Gel hydrogel; (c) Load the small extracellular vesicle suspension obtained in step (a) into the αLA-Gel hydrogel obtained in step (b) to obtain the composite hydrogel.

[0012] Further, step (a) includes: culturing human mesenchymal stem cells to a confluence of 75-85%, adding quercetin at a final concentration of 20 μM for continued culturing, and collecting the culture supernatant; centrifuging the supernatant at differential speed to remove cells and cell debris, centrifuging the supernatant after differential centrifugation at ultracentrifugation, discarding the supernatant, and resuspending the resulting precipitate in PBS; centrifuging the resuspended solution at ultracentrifugation again, discarding the supernatant, and obtaining purified small extracellular vesicle precipitate; resuspending the precipitate in PBS to obtain the small extracellular vesicle suspension.

[0013] Further, step (b) includes: dissolving gelatin methacryloyl derivative in water, adding aminomethane and α-lipoic acid at 50-60°C, reacting for 3-5 hours to obtain αLA-Gel hydrogel.

[0014] Further, step (c) includes: under sterile conditions, adding the small extracellular vesicle suspension obtained in step (a) to the αLA-Gel hydrogel obtained in step (b), and incubating at 4°C or room temperature for 2-12 hours, so that the small extracellular vesicles can penetrate into and be loaded into the porous structure of the αLA-Gel hydrogel by capillary action; after the incubation is completed, removing the unadsorbed suspension to obtain the composite hydrogel.

[0015] The third aspect is to provide the application of the above-mentioned composite hydrogel in the preparation of medical devices or biomaterials for promoting bone-tendon interface repair.

[0016] The present invention adopts the above technical solution and has the following technical effects compared with the prior art: This invention constructs a bone-tendon interface repair material by combining quercetin-pretreated small extracellular vesicles (Sm-sEVs) with α-lipoic acid-modified GelMA hydrogel (αLA-Gel), which simultaneously possesses immunomodulatory, anti-cellular aging, tissue adhesion, and sustained release functions. The main beneficial effects of this material are as follows: 1) It provides a comprehensive repair strategy against adverse microenvironments: In a rat model of osteoporosis induced by ovariectomy, the Sm-sEV / αLA-Gel composite material was shown to effectively deliver active ingredients to the damaged interface. It significantly reduced the expression of aging markers (p21 and γ-H2AX) in local tissues, indicating that the material has good anti-cellular aging ability in osteoporosis and inflammatory environments, which is beneficial to improving the regenerative microenvironment.

[0017] 2) Significantly enhanced mechanical integration strength of the bone-tendon interface: Quantitative biomechanical tests in animal experiments showed that after intervention with Sm-sEV / αLA-Gel, the failure load at the bone-tendon interface reached 27.6 ± 2.17 N at 8 weeks post-operation, which was approximately 2.1 times higher than that of the control group (13.07 ± 2.14 N). This directly proves that the material of this invention can greatly enhance the mechanical properties of interface healing, laying a solid foundation for functional recovery.

[0018] 3) Possessing both excellent material properties and biological functions: The αLA-Gel hydrogel prepared in this invention has an interconnected three-dimensional porous structure, which not only provides physical space for cell migration and tissue ingrowth, but also achieves efficient loading and controlled release of Sm-sEVs through capillary action. Combined with its inherent tissue adhesion, this material can stably reside at the injury site, enabling the continuous and localized exertion of Sm-sEV bioactivity.

[0019] In summary, the Sm-sEV / αLA-Gel composite material provided by this invention, through the synergy of its structure and function, effectively inhibited interfacial tissue aging in a complex osteoporosis animal model, and ultimately achieved a repair effect with significantly enhanced mechanical strength, demonstrating its application potential in the field of repairing refractory tendon-bone interface injuries. Attached Figure Description

[0020] Figure 1 Transmission electron micrographs of small extracellular vesicles (sEVs) and aging phenotype-regulating small extracellular vesicles (Sm-sEVs) prepared for this invention.

[0021] Figure 2 Scanning electron microscope image of the α-lipoic acid modified gelatin methacryloyl hydrogel (αLA-Gel) prepared in this invention.

[0022] Figure 3 Adhesion tests of α-lipoic acid modified GelMA hydrogel; where A is a schematic diagram of the tensile shear mechanics testing device; and B is the observation results of the adhesion of α-lipoic acid modified GelMA hydrogel on different tissue surfaces.

[0023] Figure 4 The study demonstrated that Sm-sEV / αLA-Gel implantation in an osteoporotic rat rotator cuff injury model inhibited the expression of aging-related proteins p21 and γ-H2AX.

[0024] Figure 5 This study demonstrates that Sm-sEV / αLA-Gel implantation enhances the biomechanical strength of the bone-tendon interface in an osteoporotic rat rotator cuff injury model. Detailed Implementation

[0025] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but this is not intended to limit the invention. It should be noted that, unless otherwise specified, the embodiments and features described in the embodiments of the present invention can be combined with each other.

[0026] Experimental methods in the following examples, unless otherwise specified, were performed under standard conditions or as recommended by the manufacturer. Unless otherwise stated, all reagents and materials used in the following examples were commercially available.

[0027] Example 1 This embodiment provides a method for preparing α-lipoic acid modified gelatin methacryloyl hydrogel (Sm-sEV / αLA-Gel) with quercetin-loaded quercetin-pretreated aging phenotype-regulating small extracellular vesicles.

[0028] (a) Preparation of quercetin-pretreated small extracellular vesicles (Sm-sEVs) Human adipose-derived stem cells (ADSCs) were selected as the vesicle-derived cells. ADSCs were seeded in conventional culture flasks and cultured in medium containing 10% fetal bovine serum until the cell confluence reached approximately 80%. Quercetin was then added to the culture system to a final concentration of 20 μM, and the cells were cultured for another 48 hours. After the culture was completed, all culture supernatant was collected.

[0029] The obtained supernatant was centrifuged sequentially at 300×g for 10 min, 2000×g for 20 min, and 10000×g for 30 min to remove cells and cell debris. The supernatant was then transferred to an ultracentrifuge tube and centrifuged at 100000×g for 70 min. The supernatant was discarded, and the precipitate was resuspended in PBS (Phosphate-Buffered Saline) and centrifuged again at 100000×g for 70 min to obtain the final Sm-sEV precipitate. The Sm-sEV was resuspended in an appropriate amount of PBS, aliquoted, and stored at -80°C for later use.

[0030] (b) Preparation of α-lipoic acid modified GelMA porous hydrogel (αLA-Gel) 0.17 g of gelatin methacryloyl (GelMA) was added to 5 mL of purified water and heated in a 55°C water bath until completely dissolved, yielding a homogeneous GelMA solution. 0.27 g of Tris (aminomethane, as an alkaline auxiliary and reaction promoter) was added to this solution under stirring. After complete dissolution, 0.7 g of α-lipoic acid (αLA) was added, and the reaction was continued at 55°C for 4 hours to obtain αLA-Gel hydrogel (semi-cured).

[0031] (c) Construction of Sm-sEV / αLA-Gel composite hydrogel The αLA-Gel hydrogel was placed in a sterile environment, and a pre-prepared Sm-sEV suspension was added. The mixture was incubated at 4°C or room temperature for 2–12 hours, allowing Sm-sEV to penetrate the porous structure of the hydrogel via capillary action and become loaded within the αLA-Gel. After incubation, any excess unadsorbed Sm-sEV solution was gently removed to obtain the Sm-sEV / αLA-Gel composite hydrogel.

[0032] The preparation of Sm-sEV and αLA-Gel are two independent steps that can be carried out separately and then combined in the final step, which facilitates quality control and flexible production.

[0033] Example 2 Morphological characterization of Sm-sEV and αLA-Gel 1. Transmission electron microscopy (TEM) observation of Sm-sEV Figure 1 The prepared Sm-sEVs exhibited typical cup-shaped or bilayer membrane vesicle structures with intact morphology, clear boundaries, and particle sizes mainly distributed between 50-200 nm, consistent with the morphological characteristics of small extracellular vesicles. These results confirm the successful extraction of structurally intact sEVs via quercetin pretreatment and differential ultracentrifugation.

[0034] 2. Scanning electron microscopy (SEM) observation of αLA-Gel The αLA-Gel hydrogel was transferred into a pre-prepared mold, frozen at -80°C for 24 h, and then freeze-dried in a vacuum freeze dryer for 48 h before being observed by scanning electron microscopy (SEM).

[0035] Figure 2The αLA-Gel hydrogel exhibits a layered, interconnected three-dimensional porous network structure with clearly defined, wrinkled pore walls and non-uniform pore sizes. Scale bars show that the pores are primarily distributed in the 20-200 μm range (including some micropores smaller than 50 μm). This high-porosity, interconnected structure facilitates cell migration, nutrient transport and diffusion, and allows for efficient loading of Sm-sEVs via capillary action.

[0036] Example 3 Mechanical properties and adhesion tests of αLA-Gel hydrogel 1. Testing of tensile and shear mechanical properties αLA-Gel hydrogel (semi-cured) was prepared using the method in Example 1. 0.5 mL of αLA-Gel hydrogel was drawn up using a sterile syringe and evenly spread between two plastic sheets (2 cm × 1 cm). The spread area was controlled to be 1 cm² and the thickness 0.5 mm, and these dimensional parameters were recorded. (Reference) Figure 3 A. Fix the plastic sheet vertically to both ends of the universal force gauge, apply a tensile force at a constant speed of 1 mm / min, and record the mechanical data when the tensile force reaches a stable state.

[0037] Based on the tensile shear test results, the tensile shear modulus of αLA-Gel hydrogel was calculated to be approximately 200 Pa by using the linear relationship between shear stress and shear strain.

[0038] 2. Tissue adhesion test Fresh porcine skin, skeletal muscle, femoral bone fragments, and bone-tendon interface complexes were taken, trimmed to appropriate sizes, rinsed with PBS, and kept moist for later use. αLA-Gel hydrogels (semi-cured) were prepared using the method described in Example 1.

[0039] refer to Figure 3 B. Using a sterile syringe, draw 0.5 mL of αLA-Gel hydrogel and evenly apply it to the contact surface of the "plastic sheet-target tissue," controlling the application area to be 1 cm² and the thickness to be 0.5 mm. Let it stand at room temperature for 10 minutes to allow the αLA-Gel hydrogel to fully bond with the tissue surface. Adhesion observation: Place the above "plastic sheet-αLA-Gel hydrogel-tissue" composite in a room temperature environment and continuously observe the adhesion status of the αLA-Gel hydrogel on the tissue surface (whether peeling or detachment occurs) for 1 hour.

[0040] Observations showed that αLA-Gel hydrogel exhibited good adhesion to skin, muscle, bone tissue, and bone-tendon interfaces. 1) Skin surface: αLA-Gel hydrogel adheres closely to the epidermis and does not peel or fall off within 1 hour; 2) Muscle surface: αLA-Gel hydrogel penetrates into the gaps between muscle fibers, with only slight lifting at the edges within 1 hour, while the main body remains attached; 3) Bone tissue surface: αLA-Gel hydrogel fully integrates with the rough bone surface structure, with no obvious separation within 1 hour; 4) Bone-tendon interface: The αLA-Gel hydrogel solution adheres to both the bone end and the tendon end simultaneously. The interface does not crack within 1 hour and can maintain a stable connection.

[0041] Example 4 Animal Experiment This embodiment aims to verify the effect of Sm-sEV / αLA-Gel composite hydrogel on bone-tendon interface (BTI) repair in an ovariectomy (OVX)-induced osteoporotic female SD rat model.

[0042] 1. Materials, Animals, and Grouping Material preparation: The Sm-sEV / αLA-Gel used in the experimental group was prepared strictly according to the method in Example 1. To clarify the experimental conditions, the key parameters were fixed as follows: 475 μL of αLA-Gel hydrogel was mixed with 25 μL of Sm-sEV (1 × 10⁻⁶) hydrogel. 11 The Sm-sEV / αLA-Gel composite hydrogel was prepared by mixing the PBS solution (particles / mL) and incubating at 4°C for 2 hours.

[0043] Control group material: The control group was blank αLA-Gel hydrogel, and its preparation process was exactly the same as that of the experimental group, except that the incubation solution was replaced with an equal volume of sterile PBS.

[0044] Animal model and grouping: 12-week-old female SD rats underwent bilateral OVX surgery to establish an osteoporosis model. After being fed for 12 weeks, they were randomly divided into two groups (n=6 in each group): Control group: The rotator cuff was directly sutured without hydrogel implantation.

[0045] αLA-Gel experimental group (αLA-Gel): received αLA-Gel composite hydrogel intervention.

[0046] Sm-sEV / αLA-Gel experimental group (Sm-sEV / αLA-Gel): received Sm-sEV / αLA-Gel composite hydrogel intervention.

[0047] 2. Surgery and Intervention After establishing the osteoporosis model, rats were anesthetized and sutured to create a rotator cuff (supraspinatus tendon) lesion. Subsequently, 30 μL of the appropriate group of material was uniformly injected into the tendon-bone insertion area using a microsyringe. Postoperatively, the animals were fed according to standard care.

[0048] 3. Sample collection and testing (8 weeks post-surgery) Immunofluorescence analysis: Tissue sections from the BTI region were taken to detect the aging-related protein p21 and the DNA damage marker γ-H2AX.

[0049] Biomechanical testing: Uniaxial tensile testing of the tendon-bone complex.

[0050] 4. Experimental Results Figure 4 The results showed that the expression levels of aging-related protein p21 and DNA damage marker γ-H2AX in the Sm-sEV / αLA-Gel treatment group were significantly lower than those in the αLA-Gel group and the control group (P<0.001), indicating that the material of this invention can significantly reduce the local tissue aging load under OVX-induced osteoporosis and inflammation. The sustained release of Sm-sEV and the structural support of αLA-Gel jointly improved the BTI microenvironment, which is beneficial to maintaining cell activity and regenerating and reconstructing layered tissues.

[0051] Figure 5 The results showed that the interface failure load of the control group was 13.07±2.14N, the interface failure load of the αLA-Gel group was 17.27±1.44N, while the Sm-sEV / αLA-Gel group reached 27.60±2.17N, which was about 2.1 times that of the control group, indicating that the material of the present invention significantly improved the mechanical integration capability of BTI.

[0052] In summary, Sm-sEV / αLA-Gel can still effectively inhibit interfacial tissue aging, promote bone and fibrocartilage formation, and significantly enhance the mechanical properties of the bone-tendon interface under conditions of osteoporosis induced by ovariectomy, thus verifying the superiority and application potential of the material of this invention.

[0053] The above description is merely a preferred embodiment of the present invention and does not limit the implementation and protection scope of the present invention. Those skilled in the art should realize that any equivalent substitutions and obvious changes made based on the content and illustrations of the present invention should be included within the protection scope of the present invention.

Claims

1. A composite hydrogel for bone-tendon interface repair, characterized in that, The composite hydrogel comprises quercetin-pretreated small extracellular vesicles and a gelatin methacryloyl hydrogel carrier with an α-lipoic acid modified porous structure for loading the small extracellular vesicles.

2. The composite hydrogel according to claim 1, characterized in that, The small extracellular vesicles are derived from human mesenchymal stem cells treated with quercetin.

3. The composite hydrogel according to claim 2, characterized in that, The human mesenchymal stem cells are selected from adipose-derived stem cells, bone marrow-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or induced pluripotent stem cells.

4. The composite hydrogel according to claim 3, characterized in that, The human mesenchymal stem cells mentioned are adipose-derived stem cells.

5. A method for preparing a composite hydrogel as described in any one of claims 1-4, characterized in that, Includes the following steps: (a) Preparation of a suspension of small extracellular vesicles pretreated with quercetin; (b) Prepare a porous hydrogel of gelatin methacryloyl derivative modified with α-lipoic acid, denoted as αLA-Gel hydrogel; (c) Load the small extracellular vesicle suspension obtained in step (a) into the αLA-Gel hydrogel obtained in step (b) to obtain the composite hydrogel.

6. The preparation method according to claim 5, characterized in that, Step (a) includes: culturing human mesenchymal stem cells to a confluence of 75-85%, adding quercetin at a final concentration of 20 μM and continuing the culture, and collecting the culture supernatant; centrifuging the supernatant at differential speed to remove cells and cell debris, centrifuging the supernatant after differential centrifugation at ultracentrifugation, discarding the supernatant, and resuspending the resulting precipitate in PBS; centrifuging the resuspended solution at ultracentrifugation again, discarding the supernatant, and obtaining purified small extracellular vesicle precipitate; resuspending the precipitate in PBS to obtain the small extracellular vesicle suspension.

7. The preparation method according to claim 5, characterized in that, Step (b) includes: dissolving gelatin methacryloyl derivative in water, adding aminomethane and α-lipoic acid at 50-60°C, reacting for 3-5 hours to obtain αLA-Gel hydrogel.

8. The preparation method according to claim 5, characterized in that, Step (c) includes: under sterile conditions, adding the small extracellular vesicle suspension obtained in step (a) to the αLA-Gel hydrogel obtained in step (b), and incubating at 4°C or room temperature for 2-12 hours, so that the small extracellular vesicles can penetrate into and be loaded into the porous structure of the αLA-Gel hydrogel by capillary action; after incubation, removing the unadsorbed suspension to obtain the composite hydrogel.

9. The use of the composite hydrogel according to any one of claims 1-4 in the preparation of medical devices or biomaterials for promoting bone-tendon interface repair.